Review



recombinant mouse ccl2  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    R&D Systems recombinant mouse ccl2
    Intratracheal administration of 0.5μg TNF (A and B) or 50μg poly(I:C) (C and D) to A20 AEC-KO or wild type littermates (A20 WT ). Absolute numbers of neutrophils or monocytes in bronchoalveolar lavages (BAL) as determined by flow cytometry at 6h and 24h post-treatment for TNF (A) or 24h post-treatment for poly(I:C) (C). IL-6, CXCL1 (KC), <t>CCL2</t> (MCP-1) and TNF [only for poly(I:C)] protein levels in BAL fluid detected by Multiplex immunoassay (B and D). Data represent mean ± SEM of at least 4 mice per group (*p < 0.05; Student’s t -test).
    Recombinant Mouse Ccl2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 166 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multiplex+protein+array+system+technology/Recombinant+Mouse+CCL2%2FJE%2FMCP-1+Protein/pmc04731390-147-0-3
    Average 95 stars, based on 166 article reviews
    recombinant mouse ccl2 - by Bioz Stars, 2026-11
    95/100 stars

    Images

    1) Product Images from "A20 Deficiency in Lung Epithelial Cells Protects against Influenza A Virus Infection"

    Article Title: A20 Deficiency in Lung Epithelial Cells Protects against Influenza A Virus Infection

    Journal: PLoS Pathogens

    doi: 10.1371/journal.ppat.1005410

    Intratracheal administration of 0.5μg TNF (A and B) or 50μg poly(I:C) (C and D) to A20 AEC-KO or wild type littermates (A20 WT ). Absolute numbers of neutrophils or monocytes in bronchoalveolar lavages (BAL) as determined by flow cytometry at 6h and 24h post-treatment for TNF (A) or 24h post-treatment for poly(I:C) (C). IL-6, CXCL1 (KC), CCL2 (MCP-1) and TNF [only for poly(I:C)] protein levels in BAL fluid detected by Multiplex immunoassay (B and D). Data represent mean ± SEM of at least 4 mice per group (*p < 0.05; Student’s t -test).
    Figure Legend Snippet: Intratracheal administration of 0.5μg TNF (A and B) or 50μg poly(I:C) (C and D) to A20 AEC-KO or wild type littermates (A20 WT ). Absolute numbers of neutrophils or monocytes in bronchoalveolar lavages (BAL) as determined by flow cytometry at 6h and 24h post-treatment for TNF (A) or 24h post-treatment for poly(I:C) (C). IL-6, CXCL1 (KC), CCL2 (MCP-1) and TNF [only for poly(I:C)] protein levels in BAL fluid detected by Multiplex immunoassay (B and D). Data represent mean ± SEM of at least 4 mice per group (*p < 0.05; Student’s t -test).

    Techniques Used: Flow Cytometry, Multiplex Assay

    (A) Absolute numbers of monocytes, neutrophils and alveolar macrophages in bronchoalveolar lavages (BAL) of A20 AEC-KO or A20 WT mice at 2, 5, 8 and 12 days post-infection (days p.i.) with 0.05 X LD 50 X-47. (B) Absolute numbers of resident CD11b - or recruited CD11b + macrophages in the lungs of A20 WT and A20 AEC-KO mice. (C) CCL2 (MCP-1) protein levels in BAL fluid measured by Multiplex immunoassay at indicated time points post-infection. (D) Weight loss of A20 AEC-KO and A20 WT mice infected with 0.05 X LD 50 X-47. At day 6 p.i. (indicated by an arrow) mice received intranasal treatment with 50 μg/kg recombinant CCL2 (rCCL2) or PBS. Data were analysed using Student’s t -test (A, B and C *p < 0.05) and 2-way ANOVA (D, *p < 0.05 for A20 AEC-KO PBS vs. A20 WT PBS and # p < 0.05 for A20 AEC-KO PBS vs A20 AEC-Cre rCCL2). Data represent mean ± SEM of at least 3 mice per group. Data are representative of at least 2 independent experiments.
    Figure Legend Snippet: (A) Absolute numbers of monocytes, neutrophils and alveolar macrophages in bronchoalveolar lavages (BAL) of A20 AEC-KO or A20 WT mice at 2, 5, 8 and 12 days post-infection (days p.i.) with 0.05 X LD 50 X-47. (B) Absolute numbers of resident CD11b - or recruited CD11b + macrophages in the lungs of A20 WT and A20 AEC-KO mice. (C) CCL2 (MCP-1) protein levels in BAL fluid measured by Multiplex immunoassay at indicated time points post-infection. (D) Weight loss of A20 AEC-KO and A20 WT mice infected with 0.05 X LD 50 X-47. At day 6 p.i. (indicated by an arrow) mice received intranasal treatment with 50 μg/kg recombinant CCL2 (rCCL2) or PBS. Data were analysed using Student’s t -test (A, B and C *p < 0.05) and 2-way ANOVA (D, *p < 0.05 for A20 AEC-KO PBS vs. A20 WT PBS and # p < 0.05 for A20 AEC-KO PBS vs A20 AEC-Cre rCCL2). Data represent mean ± SEM of at least 3 mice per group. Data are representative of at least 2 independent experiments.

    Techniques Used: Infection, Multiplex Assay, Recombinant

    Related Articles

    Incubation:

    Article Title: CSF1R+ macrophage and osteoclast depletion impairs neural crest proliferation and craniofacial morphogenesis.
    Article Snippet: : 60.7% DMEM (GIBCO 11965-092, Thermo Fisher Scientific), 30.3% F-12 (GIBCO 11765-054, Thermo Fisher Scientific), 2% B-27 supplement (GIBCO 17504-044, Thermo Fisher Scientific), 7% PBS, 10 ng/mL CCL2 (R&D Systems, Cat#479-JE), 20 ng/mL CCL3 (R&D Systems, Cat#450-MA), 40 ng/mL CCL4 (R&D Systems, Cat#451-MB), 20 ng/mL CCL12 (R&D Systems, Cat#428-P5), 30 ng/mL CXCL2 (R&D Systems, Cat#452-M2), 30 ng/mL

    Recombinant:

    Article Title: CSF1R+ macrophage and osteoclast depletion impairs neural crest proliferation and craniofacial morphogenesis.
    Article Snippet: : 60.7% DMEM (GIBCO 11965-092, Thermo Fisher Scientific), 30.3% F-12 (GIBCO 11765-054, Thermo Fisher Scientific), 2% B-27 supplement (GIBCO 17504-044, Thermo Fisher Scientific), 7% PBS, 10 ng/mL CCL2 (R&D Systems, Cat#479-JE), 20 ng/mL CCL3 (R&D Systems, Cat#450-MA), 40 ng/mL CCL4 (R&D Systems, Cat#451-MB), 20 ng/mL CCL12 (R&D Systems, Cat#428-P5), 30 ng/mL CXCL2 (R&D Systems, Cat#452-M2), 30 ng/mL

    Mouse Assay:

    Article Title: CSF1R+ macrophage and osteoclast depletion impairs neural crest proliferation and craniofacial morphogenesis.
    Article Snippet: : 60.7% DMEM (GIBCO 11965-092, Thermo Fisher Scientific), 30.3% F-12 (GIBCO 11765-054, Thermo Fisher Scientific), 2% B-27 supplement (GIBCO 17504-044, Thermo Fisher Scientific), 7% PBS, 10 ng/mL CCL2 (R&D Systems, Cat#479-JE), 20 ng/mL CCL3 (R&D Systems, Cat#450-MA), 40 ng/mL CCL4 (R&D Systems, Cat#451-MB), 20 ng/mL CCL12 (R&D Systems, Cat#428-P5), 30 ng/mL CXCL2 (R&D Systems, Cat#452-M2), 30 ng/mL

    Injection:

    Article Title: CSF1R+ macrophage and osteoclast depletion impairs neural crest proliferation and craniofacial morphogenesis.
    Article Snippet: : 60.7% DMEM (GIBCO 11965-092, Thermo Fisher Scientific), 30.3% F-12 (GIBCO 11765-054, Thermo Fisher Scientific), 2% B-27 supplement (GIBCO 17504-044, Thermo Fisher Scientific), 7% PBS, 10 ng/mL CCL2 (R&D Systems, Cat#479-JE), 20 ng/mL CCL3 (R&D Systems, Cat#450-MA), 40 ng/mL CCL4 (R&D Systems, Cat#451-MB), 20 ng/mL CCL12 (R&D Systems, Cat#428-P5), 30 ng/mL CXCL2 (R&D Systems, Cat#452-M2), 30 ng/mL

    RNAscope:

    Article Title: CSF1R+ macrophage and osteoclast depletion impairs neural crest proliferation and craniofacial morphogenesis.
    Article Snippet: : 60.7% DMEM (GIBCO 11965-092, Thermo Fisher Scientific), 30.3% F-12 (GIBCO 11765-054, Thermo Fisher Scientific), 2% B-27 supplement (GIBCO 17504-044, Thermo Fisher Scientific), 7% PBS, 10 ng/mL CCL2 (R&D Systems, Cat#479-JE), 20 ng/mL CCL3 (R&D Systems, Cat#450-MA), 40 ng/mL CCL4 (R&D Systems, Cat#451-MB), 20 ng/mL CCL12 (R&D Systems, Cat#428-P5), 30 ng/mL CXCL2 (R&D Systems, Cat#452-M2), 30 ng/mL

    Isolation:

    Article Title: CSF1R+ macrophage and osteoclast depletion impairs neural crest proliferation and craniofacial morphogenesis.
    Article Snippet: : 60.7% DMEM (GIBCO 11965-092, Thermo Fisher Scientific), 30.3% F-12 (GIBCO 11765-054, Thermo Fisher Scientific), 2% B-27 supplement (GIBCO 17504-044, Thermo Fisher Scientific), 7% PBS, 10 ng/mL CCL2 (R&D Systems, Cat#479-JE), 20 ng/mL CCL3 (R&D Systems, Cat#450-MA), 40 ng/mL CCL4 (R&D Systems, Cat#451-MB), 20 ng/mL CCL12 (R&D Systems, Cat#428-P5), 30 ng/mL CXCL2 (R&D Systems, Cat#452-M2), 30 ng/mL

    Multiplex Assay:

    Article Title: CSF1R+ macrophage and osteoclast depletion impairs neural crest proliferation and craniofacial morphogenesis.
    Article Snippet: : 60.7% DMEM (GIBCO 11965-092, Thermo Fisher Scientific), 30.3% F-12 (GIBCO 11765-054, Thermo Fisher Scientific), 2% B-27 supplement (GIBCO 17504-044, Thermo Fisher Scientific), 7% PBS, 10 ng/mL CCL2 (R&D Systems, Cat#479-JE), 20 ng/mL CCL3 (R&D Systems, Cat#450-MA), 40 ng/mL CCL4 (R&D Systems, Cat#451-MB), 20 ng/mL CCL12 (R&D Systems, Cat#428-P5), 30 ng/mL CXCL2 (R&D Systems, Cat#452-M2), 30 ng/mL



    Similar Products

    86
    DiaSorin Biotechnology multiplex protein array technology
    Multiplex Protein Array Technology, supplied by DiaSorin Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multiplex+protein+array+system+technology/pmc04304418-12-31-35
    Average 86 stars, based on 1 article reviews
    multiplex protein array technology - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    92
    Bio-Rad multiplex protein array system technology
    Multiplex Protein Array System Technology, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multiplex+protein+array+system+technology/ProteOn+Multiple+Protein+Interaction+Kit/10__1158_slash_0008___5472__can___09___1627-65-5-10
    Average 92 stars, based on 1 article reviews
    multiplex protein array system technology - by Bioz Stars, 2026-11
    92/100 stars
      Buy from Supplier

    Image Search Results